Floatz logo

dn-101

Friedreich Ataxia

Berta AlemanySmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Friedreich Ataxia cohort.

Asset / SponsorPhaseRating
Omaveloxolone
Biogen
Phase 3BB
CITALOPRAM
University of Colorado, Denver
Phase 4BB
Wellbutrin
University of Colorado, Denver
Phase 4BB
Trans-Resveratrol
Murdoch Childrens Research Institute
Phase 2BB
Vatiquinone
PTC Therapeutics
Phase 3BB

View all 28 →

Same molecule, other indications

dn-101 is also rated in:

PsoriasisDormant
B
Indicative ·
59 / 100
View asset →
Facial AngiofibromaDormant
B
Indicative ·
59 / 100
View asset →
Cholestatic Liver DiseaseDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →